The effects of cyclooxygenase-2 gene silencing by siRNA on cell proliferation,             cell apoptosis, cell cycle and tumorigenicity of Capan-2 human pancreatic cancer             cells.
The prognosis of pancreatic cancer is still very poor. No specific effective             gene therapy for pancreatic cancer has been found. As a key enzyme of the metabolic             process of arachidonic acid, cyclooxygenase-2 (COX-2) has been found to be closely             related to the tumorigenesis of epithelial cancers. However, the antitumor effect             of small interfering RNA (siRNA) targeting COX-2 in pancreatic cancer has not             yet been verified. Therefore, the aim of this study was to investigate the effects             of COX-2 gene silencing by siRNA on cell proliferation, cell apoptosis, cell cycle             and tumorigenicity of pancreatic cancer cells. COX-2 mRNA was detected by RT-PCR             and real-time PCR. COX-2 protein was detected by Western blotting. The cell proliferation             was measured by cell counting using microscopy. The cell apoptosis and cell cycle             were measured by flow cytometry. The tumorigenicity of Capan-2 pancreatic cancer             cells transfected with COX-2 siRNA was evaluated using a nude mouse xenograft             model. The expression of COX-2 mRNA as well as COX-2 protein were downregulated             after COX-2 siRNA transfection. COX-2 siRNA could inhibit the growth of Capan-2             cells significantly by decreasing the cell proliferation, increasing cell apoptosis             and regulating cell cycle as well. In vivo experiments demonstrated that the mean             volume and weight of subcutaneous xenografts in nude mice derived from Capan-2             cells transfected with COX-2 siRNA were significantly decreased. COX-2 siRNA could             inhibit the growth of Capan-2 pancreatic cancer cells and also decrease the tumorigenicity             of Capan-2 cells, implicating a new potential therapeutic target in pancreatic             cancer.
Department of Gastroenterology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, PR China.
Yingqiang
Y
Zhong
Zhongsheng
Z
Xia
Juan
J
Liu
Ying
Y
Lin
Hui
H
Zan
D000818:Animals; D017209:Apoptosis; D015153:Blotting, Western; D002453:Cell Cycle; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002470:Cell Survival; D051546:Cyclooxygenase 2 / Q000172:deficiency* / Q000235:genetics; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D010190:Pancreatic Neoplasms / Q000201:enzymology* / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D034622:RNA Interference; D060888:Real-Time Polymerase Chain Reaction; D013997:Time Factors; D014162:Transfection; D047368:Tumor Burden; D023041:Xenograft Model Antitumor Assays
D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human